Compare NUTX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | GHRS |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | Ireland |
| Employees | 800 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2009 | 2021 |
| Metric | NUTX | GHRS |
|---|---|---|
| Price | $112.00 | $14.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $252.50 | $35.00 |
| AVG Volume (30 Days) | ★ 186.5K | 167.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13971.43 | N/A |
| EPS | ★ 8.87 | N/A |
| Revenue | ★ $479,948,633.00 | N/A |
| Revenue This Year | $108.77 | N/A |
| Revenue Next Year | $3.69 | N/A |
| P/E Ratio | $12.91 | ★ N/A |
| Revenue Growth | ★ 93.80 | N/A |
| 52 Week Low | $40.67 | $7.98 |
| 52 Week High | $193.07 | $19.51 |
| Indicator | NUTX | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 44.15 |
| Support Level | $106.92 | $12.54 |
| Resistance Level | $139.71 | $14.80 |
| Average True Range (ATR) | 8.71 | 0.78 |
| MACD | 2.46 | -0.06 |
| Stochastic Oscillator | 66.79 | 16.00 |
Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.